Aileron Therapeutics, Inc. (ALRN) Expected to Post Q1 2018 Earnings of ($0.49) Per Share

Aileron Therapeutics, Inc. (NASDAQ:ALRN) – Analysts at William Blair issued their Q1 2018 EPS estimates for shares of Aileron Therapeutics in a report released on Friday. William Blair analyst Y. Xu expects that the company will earn ($0.49) per share for the quarter. William Blair currently has a “Outperform” rating on the stock.

Several other research analysts have also weighed in on ALRN. Canaccord Genuity reaffirmed a “buy” rating and set a $19.00 price target on shares of Aileron Therapeutics in a research report on Friday, August 11th. Bank of America Corporation assumed coverage on Aileron Therapeutics in a research report on Monday, July 24th. They set a “buy” rating and a $19.00 price target on the stock. Finally, Jefferies Group LLC assumed coverage on Aileron Therapeutics in a research report on Monday, July 24th. They set a “buy” rating and a $20.00 price target on the stock.

ILLEGAL ACTIVITY NOTICE: “Aileron Therapeutics, Inc. (ALRN) Expected to Post Q1 2018 Earnings of ($0.49) Per Share” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/14/aileron-therapeutics-inc-alrn-expected-to-post-q1-2018-earnings-of-0-49-per-share.html.

Aileron Therapeutics (NASDAQ:ALRN) opened at $11.78 on Monday. Aileron Therapeutics has a 1 year low of $9.58 and a 1 year high of $15.48.

Several large investors have recently bought and sold shares of ALRN. Jennison Associates LLC acquired a new position in shares of Aileron Therapeutics during the 2nd quarter worth approximately $2,788,000. Candriam Luxembourg S.C.A. acquired a new position in shares of Aileron Therapeutics during the 2nd quarter worth approximately $1,673,000. Sphera Funds Management LTD. acquired a new position in shares of Aileron Therapeutics during the 2nd quarter worth approximately $1,394,000. Nexthera Capital LP acquired a new position in shares of Aileron Therapeutics during the 2nd quarter worth approximately $1,272,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Aileron Therapeutics during the 2nd quarter worth approximately $418,000. 12.39% of the stock is currently owned by hedge funds and other institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply